Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 18/20 | 0.81 |
| ▸ | PIM1 | P11309 | 4/20 | 0.71 |
| ▸ | AKT2 | P31751 | 4/20 | 0.71 |
| ▸ | GSK3A | P49840 | 4/20 | 0.71 |
| ▸ | GSK3B | P49841 | 4/20 | 0.71 |
| ▸ | RPS6KA3 | P51812 | 4/20 | 0.71 |
| ▸ | PRKCD | Q05655 | 4/20 | 0.71 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.71 |
| ▸ | AKT3 | Q9Y243 | 4/20 | 0.71 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.71 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.71 |
| ▸ | PRKD2 | Q9BZL6 | 3/20 | 0.71 |
| ▸ | PIM2 | Q9P1W9 | 3/20 | 0.71 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.71 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.71 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.71 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.71 |
| ▸ | PRKCG | P05129 | 3/20 | 0.71 |
| ▸ | PRKACA | P17612 | 3/20 | 0.71 |
| ▸ | CLK2 | P49760 | 3/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6851363 | 1.00 | AKT1 (0.81) | AKT1PIM1AKT2GSK3AGSK3B | |
| SCHEMBL7248362 | 0.88 | AKT1 (1.00) | AKT1PIM1AKT2GSK3AGSK3B | |
| SCHEMBL6850590 | 0.88 | AKT1 (1.00) | AKT1PIM1AKT2GSK3AGSK3B | |
| SCHEMBL6850583 | 0.88 | AKT1 (1.00) | AKT1PIM1AKT2GSK3AGSK3B | |
| SCHEMBL6853687 | 0.87 | AKT1 (0.73) | AKT1PIM1AKT2GSK3AGSK3B | |
| SCHEMBL6853693 | 0.86 | AKT1 (0.71) | AKT1PIM1AKT2GSK3AGSK3B | |
| SCHEMBL6853697 | 0.86 | AKT1 (0.71) | AKT1PIM1AKT2GSK3AGSK3B | |
| SCHEMBL6932390 | 0.86 | AKT1 (0.71) | AKT1PIM1AKT2GSK3AGSK3B | |
| SCHEMBL6855160 | 0.86 | AKT1 (0.81) | AKT1PIM1AKT2GSK3AGSK3B | |
| SCHEMBL6855173 | 0.86 | AKT1 (0.81) | AKT1PIM1AKT2GSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6831175-B2 | Such as N,N-dimethyl-N-(2-((5-((E)-2-pyridin-4-ylvinyl) pyridin-3-yl)oxy)ethyl)amine | ABBOTT LABORATORIES | 2004-12-14 | — | — | US | claimed |
| EP-1463505-A2 | 3-(PHENYL-ALKOXY)-5-(PHENYL)-PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | Abbott Laboratories (US) | 2004-10-06 | — | — | EP | claimed |
| US-20030187026-A1 | Kinase inhibitors | ABBOTT LABORATORIES | 2003-10-02 | — | — | US | claimed |
| WO-2003051366-A2 | 3-(PHENYL-ALKOXY)-5-(PHENYL)-PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ABBOTT LABORATORIES (US) | 2003-06-26 | — | — | WO | claimed |
| US-6831175-B2 | Such as N,N-dimethyl-N-(2-((5-((E)-2-pyridin-4-ylvinyl) pyridin-3-yl)oxy)ethyl)amine | ABBOTT LABORATORIES | 2004-12-14 | — | — | US | disclosed |
| EP-1463505-A2 | 3-(PHENYL-ALKOXY)-5-(PHENYL)-PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | Abbott Laboratories (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20030199511-A1 | Kinase inhibitors | ABBVIE INC. | 2003-10-23 | — | — | US | disclosed |
| US-20030187026-A1 | Kinase inhibitors | ABBOTT LABORATORIES | 2003-10-02 | — | — | US | disclosed |
| WO-2003051366-A2 | 3-(PHENYL-ALKOXY)-5-(PHENYL)-PYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ABBOTT LABORATORIES (US) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187026-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | AKT1 119/4885PIM1 389/4885AKT2 151/4885 |
| US-20030199511-A1 | Kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | AKT1 119/4885PIM1 389/4885AKT2 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.